Oncternal Therapeutics (ONCT) News Today → Amazon's betting big on this unknown AI company (From Manward Press) (Ad) Free ONCT Stock Alerts $8.84 +0.22 (+2.55%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 5:26 AM | americanbankingnews.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) to Post Q1 2025 Earnings of ($2.42) Per Share, HC Wainwright ForecastsMay 15 at 2:52 AM | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) PT Lowered to $19.00 at HC WainwrightMay 11, 2024 | msn.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call TranscriptMay 11, 2024 | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.comMay 10, 2024 | finance.yahoo.comQ1 2024 Oncternal Therapeutics Inc Earnings CallMay 9, 2024 | msn.comONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | sfgate.comOncternal Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comOncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsMay 8, 2024 | markets.businessinsider.comOncternal Therapeutics earnings: here's what Wall Street expectsMay 8, 2024 | americanbankingnews.comOncternal Therapeutics (ONCT) Scheduled to Post Quarterly Earnings on ThursdayMay 7, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)May 2, 2024 | globenewswire.comOncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comOncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)April 19, 2024 | uk.finance.yahoo.comEwing Sarcoma Drug Pipeline Market Research 2024: Insights About 25+ Companies and 25+ Pipeline DrugsApril 18, 2024 | globenewswire.comOncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerApril 17, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)April 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming CatalystsApril 14, 2024 | insidermonkey.com5 Buy-Rated Stocks with Latest Insider PurchasesApril 11, 2024 | finance.yahoo.comAIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USAApril 11, 2024 | insidertrades.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Acquires $27,650.56 in StockApril 2, 2024 | insidertrades.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Robert James Wills Purchases 6,914 SharesMarch 15, 2024 | globenewswire.comOncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate CancerMarch 13, 2024 | markets.businessinsider.comNorthland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)March 10, 2024 | finance.yahoo.comOncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 8, 2024 | finance.yahoo.comQ4 2023 Oncternal Therapeutics Inc Earnings CallMarch 8, 2024 | msn.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | benzinga.comOncternal Therapeutics's Earnings: A PreviewMarch 7, 2024 | msn.comONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023March 7, 2024 | benzinga.comRecap: Oncternal Therapeutics Q4 EarningsMarch 7, 2024 | washingtonpost.comOncternal Therapeutics: Q4 Earnings SnapshotMarch 7, 2024 | globenewswire.comOncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | markets.businessinsider.comOncternal Therapeutics earnings: here's what to expectFebruary 29, 2024 | globenewswire.comOncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial ResultsFebruary 25, 2024 | finance.yahoo.comOncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash WiselyFebruary 6, 2024 | finance.yahoo.comOncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 3, 2024 | morningstar.comOncternal Therapeutics Inc ONCTJanuary 30, 2024 | ca.finance.yahoo.comONCT Jul 2024 7.500 callJanuary 30, 2024 | ca.finance.yahoo.comONCT Apr 2024 2.500 callJanuary 8, 2024 | finance.yahoo.comOncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerJanuary 8, 2024 | marketbeat.comTrading was temporarily halted for "ONCT" at 07:01 PM with a stated reason of "News pending."January 4, 2024 | msn.comOncternal Therapeutics announces a reverse stock splitJanuary 4, 2024 | finance.yahoo.comOncternal Therapeutics Announces Reverse Stock SplitDecember 26, 2023 | nasdaq.comOncternal Therapeutics Updates Early Disease Response Data For ONCT-808; Shares FallDecember 26, 2023 | msn.comOncternal Therapeutics Reports Patient Death In Mid-Stage Blood Cancer Study Treated With Second Dose LevelDecember 26, 2023 | finance.yahoo.comOncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell LymphomaDecember 21, 2023 | benzinga.comOncternal Therapeutics Stock (NASDAQ:ONCT) Dividends: History, Yield and DatesDecember 4, 2023 | realmoney.thestreet.comOncternal Therapeutics upgraded to Buy from Hold at BrooklineNovember 11, 2023 | finance.yahoo.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | markets.businessinsider.comBuy Rating for Oncternal Therapeutics: Promising Clinical Programs and Potential Catalysts Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address He cracked the code to crypto… (Ad)Juan Villaverde has cracked the code to crypto. Click now for the best way into the newest AI projects ONCT Media Mentions By Week ONCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONCT News Sentiment▼0.430.55▲Average Medical News Sentiment ONCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONCT Articles This Week▼141▲ONCT Articles Average Week Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ITRM News QLI News FBRX News LUMO News BIOR News LPCN News UBX News LSTA News ACST News TXMD News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONCT) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsGold Set to EXPLODE!Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
